IL-PROJECT44
14.9.2021 10:32:07 CEST | Business Wire | Press release
project44 , the leader in real-time supply chain visibility and a Google Premier Visibility Provider, today announced a new partnership with Google Cloud to provide customers with better, real-time visibility into their supply chains. Under this partnership, project44 will be the first strategic partner for real-time transportation visibility to integrate its capabilities into Google Cloud’s Supply Chain Twin solution to provide joint customers with a view into the supply chain network, including data across all modes, existing integrations at scale, and strong relationships with other partners included in the offering.
“We’re excited to team up with project44 as the first strategic partner for real-time visibility in Google Cloud’s Supply Chain Twin solution. project44’s broad visibility network, workflow automation and predictive analytics enable collaboration across all facets of the supply chain,” said Hans Thalbauer, managing director, global supply chain and logistics industry solutions for Google Cloud. “project44’s incredible expertise in transportation provides customers with the technology needed to greatly improve insight into shipments and orders across their supply chain.”
Google Cloud supply chain solutions, particularly the Supply Chain Twin, deliver end-to-end visibility by bringing together data from various business systems such as enterprise resource planning (ERP), transportation management systems (TMS), and warehouse management systems (WMS), as well as data from the operational systems of the customer and those of their partners. The increased transportation visibility and reporting provided by project44 will provide customers with visibility into data relating to shipments once they have left suppliers, as well as when inventory is moving between warehouses and manufacturing plants, and into customers’ hands.
The project44 Platform currently supports more than 680 global shippers and logistics service providers, providing visibility into a network of more than 113,500 multimodal carrier integrations and 2.6M assets – the largest carrier network available in a single platform today.
“It’s incredibly validating to be selected as the first strategic visibility partner for Google Cloud and its new Supply Chain Twin solution,” said Jett McCandless, CEO and founder of project44. “Taking an integrated, data-first approach to solving the world’s most complex supply chain challenges will have significant benefits for customers who rely on accurate, real-time data to deliver outstanding experiences for their own customers.”
A Partnership for Growth
project44 is the fastest growing SaaS platform for real-time, end-to-end transportation visibility. Integrating with Google Cloud’s Supply Chain Twin is the latest step in project44’s aggressive plans which focus on organic growth, strategic acquisitions and partnerships, and geographic expansion. Having project44 data on Google Cloud’s BigQuery builds on their shared vision of highly available access to data and data-led decision making to improve operations as both customer expectations and supply chain disruptions keep rising.
Named as a Leader in the 2021 Gartner Magic Quadrant for Real-time Transportation Visibility , project44 continues to invest in platform, ecosystem and data science capabilities that deliver the most complete end-to-end supply chain visibility. The company announced record growth in Q2, including enterprise net dollar retention of 129% and 123% year-over-year growth in ARR. Already the largest visibility platform company as measured by ARR, customer count, and carriers, project44’s ARR in Q2 was more than the sum of the next top six visibility companies combined for the same quarter.
For more information on the Google Cloud Supply Chain Twin powered by project44, click here .
About project44
project44 is the world’s leading advanced visibility platform for shippers and logistics service providers. project44 connects, automates and provides visibility into key transportation processes to accelerate insights and shorten the time it takes to turn those insights into actions. Leveraging the power of the project44 cloud-based platform, organizations increase operational efficiencies, reduce costs, improve shipping performance, and deliver an exceptional experience to their customers. Connected to thousands of carriers worldwide and having comprehensive coverage for all ELD and telematics devices on the market, project44 supports all transportation modes and shipping types, including Air, Parcel, Final-Mile, Less-than-Truckload, Volume Less-than-Truckload, Groupage, Truckload, Rail, Intermodal, and Ocean. In 2021, project44 was named a Leader among Real-Time Transportation Visibility Providers in Gartner’s Magic Quadrant. To learn more, visit project44.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210914005253/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom